EVMN
Evommune, Inc.
$15.51
-$9.67 (-38.45%)Today
Key Statistics
Market cap558.64M
Price-Earnings ratio-4.83
Dividend yield—
Average volume669.47K
High today$18.30
Low today$15.47
Open price$17.54
Volume5.68M
52 Week high$33.20
52 Week low$13.88
Evommune, Inc.
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California.